SPECT Analysis of Cardiac Perfusion Changes After Whole-Breast/Chest Wall Radiation Therapy With or Without Active Breathing Coordinator: Results of a Randomized Phase 3 Trial

被引:53
|
作者
Zellars, Richard [1 ]
Bravo, Paco E. [2 ]
Tryggestad, Erik [3 ]
Hopfer, Kari [4 ]
Myers, Lee [1 ]
Tahari, Abdel [1 ]
Asrari, Fariba [1 ]
Ziessman, Harvey [1 ]
Garrett-Mayer, Elizabeth [5 ]
机构
[1] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
[2] Univ Washington, Med Ctr, Seattle, WA 98195 USA
[3] Mayo Clin, Rochester, MN USA
[4] Med Coll Penn & Hahnemann Univ, Philadelphia, PA USA
[5] Med Univ S Carolina, Charleston, SC 29425 USA
关键词
CANCER PATIENTS; HEART; RADIOTHERAPY;
D O I
10.1016/j.ijrobp.2013.12.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Cardiac muscle perfusion, as determined by single-photon emission computed tomography (SPECT), decreases after breast and/or chest wall (BCW) irradiation. The active breathing coordinator (ABC) enables radiation delivery when the BCW is farther from the heart, thereby decreasing cardiac exposure. We hypothesized that ABC would prevent radiation-induced cardiac toxicity and conducted a randomized controlled trial evaluating myocardial perfusion changes after radiation for left-sided breast cancer with or without ABC. Methods and Materials: Stages I to III left breast cancer patients requiring adjuvant radiation therapy (XRT) were randomized to ABC or No-ABC. Myocardial perfusion was evaluated by SPECT scans (before and 6 months after BCW radiation) using 2 methods: (1) fully automated quantitative polar mapping; and (2) semiquantitative visual assessment. The left ventricle was divided into 20 segments for the polar map and 17 segments for the visual method. Segments were grouped by anatomical rings (apical, mid, basal) or by coronary artery distribution. For the visual method, 2 nuclear medicine physicians, blinded to treatment groups, scored each segment's perfusion. Scores were analyzed with nonparametric tests and linear regression. Results: Between 2006 and 2010, 57 patients were enrolled and 43 were available for analysis. The cohorts were well matched. The apical and left anterior descending coronary artery segments had significant decreases in perfusion on SPECT scans in both ABC and No-ABC cohorts. In unadjusted and adjusted analyses, controlling for pretreatment perfusion score, age, and chemotherapy, ABC was not significantly associated with prevention of perfusion deficits. Conclusions: In this randomized controlled trial, ABC does not appear to prevent radiation-induced cardiac perfusion deficits. (C) 2014 Elsevier Inc.
引用
收藏
页码:778 / 785
页数:8
相关论文
共 41 条
  • [31] Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA)
    Sperduto, Paul W.
    Shanley, Ryan
    Luo, Xianghua
    Andrews, David
    Werner-Wasik, Maria
    Valicenti, Richard
    Bahary, Jean-Paul
    Souhami, Luis
    Won, Minhee
    Mehta, Minesh
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (03): : 526 - 531
  • [32] Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial
    Bucknell, Nicholas W.
    Kron, Tomas
    Herschtal, Alan
    Hardcastle, Nicholas
    Irving, Louis
    Macmanus, Michael
    Hanna, Gerard G.
    Moore, Alisha
    Murnane, Andrew
    Siva, Shankar
    Ball, David
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : 378 - 386
  • [33] Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole Brain Radiation Therapy (WBRT) Versus WBRT Plus Stereotactic Radiosurgery (SRS) in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA)
    Sperduto, P. W.
    Shanley, R.
    Luo, X.
    Andrews, D.
    Werner-Wasik, M.
    Valicenti, R.
    Bahary, J.
    Souhami, L.
    Won, M.
    Mehta, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S51 - S52
  • [34] Repeated Measure Analysis of Dermatitis Symptoms Evolution and Patient-Reported Outcome in N06C4: A Phase 3 Randomized Trial of Mometasone Furoate in Breast Cancer Patients Receiving Radiation Therapy
    Sio, T. T.
    Schwartz, D. J.
    Atherton, P. J.
    Wittich, M. A. Neben
    Griffin, P. C.
    Martenson, J. A.
    Sloan, J. A.
    Morton, R. F.
    Loprinzi, C. L.
    Miller, R. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S116 - S117
  • [35] Thiel et al. High-dose methotrexate with or without whole brain radiation therapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomized, non-inferiority trial. Lancet Oncol 2010. (15)
    Gibbs, Iris C.
    Shoo, B. Aika
    International Journal of Radiation Oncology Biology Physics, 2014, 90 (04): : 722 - 723
  • [36] Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)
    Chan, A.
    Delaloge, S.
    Holmes, F. A.
    Moy, B.
    Iwata, H.
    Harker, G.
    Masuda, N.
    Neskovic Konstantinovic, Z. B.
    Petrakova, K.
    Guerrero Zotano, A. L.
    Lannotti, N.
    Rodriguez, G. I.
    Tassone, P.
    von Minckwitz, G.
    Ejlertsen, B.
    Chia, S. K. L.
    Mansi, J.
    Barrios, C. H.
    Buyse, M.
    Wong, A.
    Bryce, R.
    Ye, Y.
    Martin, M.
    CANCER RESEARCH, 2016, 76
  • [37] FIVE-YEAR SAFETY AND EFFICACY OF GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS ANTI-TUMOR NECROSIS FACTOR THERAPY: FINAL STUDY RESULTS OF THE PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED GO-AFTER TRIAL
    Smolen, J. S.
    Kay, J.
    Landewe, R.
    Matteson, E. L.
    Gaylis, N.
    Wollenhaupt, J.
    Murphy, F. T.
    Han, C.
    Gathany, T.
    Xu, S.
    Zhou, Y.
    Hsia, C.
    Doyle, M. K.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 232 - 232
  • [38] Phase II randomized trial of capecitabine 1 radiation therapy with/without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival
    Gravalos, C.
    Capdevila, J.
    Layos, L.
    Pericay, C.
    Martinez-Villacampa, M.
    Lopez Lopez, C.
    Losa, F.
    Safont, M. J.
    Gomez-Espana, A.
    Alonso, V.
    Escudero, P.
    Gallego, J.
    Garcia-Paredes, B.
    Palacios, A.
    Biondo, S.
    Salazar, R.
    Aranda Aguilar, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis.
    Francolini, Giulio
    Garlatti, Pietro
    Loi, Mauro
    Detti, Beatrice
    Aquilano, Michele
    Allegra, Andrea
    Guerrieri, Barbara
    Salvestrini, Viola
    Pinzani, Pamela
    Bellini, Chiara
    Salvianti, Francesca
    Stocchi, Giulia
    Ciccone, Lucia Pia
    Salvatore, Giulia
    Sottili, Mariangela
    Di Cataldo, Vanessa
    Desideri, Isacco
    Mangoni, Monica
    Meattini, Icro
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [40] NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+BREAST CANCER: 5-YEAR INTERIM ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET).
    Martin, Miguel
    Buyse, Marc
    Devoto, Jeannette
    Xu, Feng
    Wong, Alvin
    Chan, Arlene
    ONCOLOGY NURSING FORUM, 2017, 44 (02)